KAHR Bio Australia

KAHR Medical is a clinical-stage biopharmaceutical company pioneering the development of Dual Signaling Proteins (DSP), a novel class of multi-functional biological drugs. The company's proprietary platform creates fusion proteins that simultaneously target two different pathways: blocking "don't eat me" signals used by cancer cells to evade the immune system and activating "eat me" or "attack" signals to stimulate immune responses. Its lead program, DSP107, is a first-in-class CD47-targeted therapy that also activates 4-1BB, currently being evaluated in Phase 1/2 trials for solid tumors and hematological malignancies. KAHR's pipeline also includes preclinical candidates like DSP502 and DSP216, which target other immune checkpoints and costimulatory pathways to address unmet needs in oncology. The company leverages its unique protein engineering capabilities to develop next-generation immunotherapies that aim to overcome the limitations of current checkpoint inhibitors.